Activin inhibits telomerase activity in cancer

Biochemical and Biophysical Research Communications

Volumn 389, Issue 4, 2009, Pages 668-672

  Katik, Indzi ^a   Mackenzie Kludas, Charley ^a   Nicholls, Craig ^a   Jiang, Fang Xu ^b   Zhou, Shufeng ^c   Li, He ^a   Liu, Jun Ping ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c RMIT UNIVERSITY   (Australia)

Author keywords

Activin; Cancer; Telomerase

Indexed keywords

ACTIVIN A; SMAD3 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE REPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ACTIVINS; DOWN-REGULATION; HELA CELLS; HUMANS; NEOPLASMS; RECOMBINANT PROTEINS; TELOMERASE; TUMOR SUPPRESSOR PROTEINS;

EID: 70349748780     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.09.055     Document Type: Article

References (26)

1. Tsuchida K., Nakatani M., Matsuzaki T., Yamakawa N., Liu Z., Bao Y., Arai K.Y., Murakami T., Takehara Y., Kurisaki A., and Sugino H. Novel factors in regulation of activin signaling. Mol. Cell. Endocrinol. 225 (2004) 1-8
2. Vale W., Wiater E., Gray P., Harrison C., Bilezikjian L., and Choe S. Activins and inhibins and their signaling. Ann. NY Acad. Sci. 1038 (2004) 142-147
3. Lin X., Duan X., Liang Y.Y., Su Y., Wrighton K.H., Long J., Hu M., Davis C.M., Wang J., Brunicardi F.C., Shi Y., Chen Y.G., Meng A., and Feng X.H. PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell 125 (2006) 915-928
4. Adkins H.B., Bianco C., Schiffer S.G., Rayhorn P., Zafari M., Cheung A.E., Orozco O., Olson D., De Luca A., Chen L.L., Miatkowski K., Benjamin C., Normanno N., Williams K.P., Jarpe M., LePage D., Salomon D., and Sanicola M. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J. Clin. Invest. 112 (2003) 575-587
5. Razanajaona D., Joguet S., Ay A.S., Treilleux I., Goddard-Leon S., Bartholin L., and Rimokh R. Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth. Cancer Res. 67 (2007) 7223-7229
6. Burdette J.E., and Woodruff T.K. Activin and estrogen crosstalk regulates transcription in human breast cancer cells. Endocrinol. Relat. Cancer 14 (2007) 679-689
7. Ramachandran A., Marshall E.S., Love D.R., Baguley B.C., and Shelling A.N. Activin is a potent growth suppressor of epithelial ovarian cancer cells. Cancer Lett. (2009)
8. Panopoulou E., Murphy C., Rasmussen H., Bagli E., Rofstad E.K., and Fotsis T. Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms. Cancer Res. 65 (2005) 1877-1886
9. Hempen P.M., Zhang L., Bansal R.K., Iacobuzio-Donahue C.A., Murphy K.M., Maitra A., Vogelstein B., Whitehead R.H., Markowitz S.D., Willson J.K., Yeo C.J., Hruban R.H., and Kern S.E. Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. Cancer Res. 63 (2003) 994-999
10. Deacu E., Mori Y., Sato F., Yin J., Olaru A., Sterian A., Xu Y., Wang S., Schulmann K., Berki A., Kan T., Abraham J.M., and Meltzer S.J. Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes. Cancer Res. 64 (2004) 7690-7696
11. Su G.H., Bansal R., Murphy K.M., Montgomery E., Yeo C.J., Hruban R.H., and Kern S.E. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc. Natl. Acad. Sci. USA 98 (2001) 3254-3257
12. Jeruss J.S., Sturgis C.D., Rademaker A.W., and Woodruff T.K. Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. Cancer Res. 63 (2003) 3783-3790
13. Li H., and Liu J.P. Mechanisms of action of TGF-beta in cancer: evidence for Smad3 as a repressor of the hTERT gene. Ann. NY Acad. Sci. 1114 (2007) 56-68
14. Li H., Xu D., Toh B.H., and Liu J.P. TGF-beta and cancer: is Smad3 a repressor of hTERT gene?. Cell Res. 16 (2006) 169-173
15. Li H., Xu D., Li J., Berndt M.C., and Liu J.P. Transforming growth factor beta suppresses human telomerase reverse transcriptase (hTERT) by Smad3 interactions with c-Myc and the hTERT gene. J. Biol. Chem. 281 (2006) 25588-25600
16. Cassar L., Li H., Pinto A.R., Nicholls C., Bayne S., and Liu J.P. Bone morphogenetic protein-7 inhibits telomerase activity, telomere maintenance, and cervical tumor growth. Cancer Res. 68 (2008) 9157-9166
17. Shay J.W., and Wright W.E. Telomerase therapeutics for cancer: challenges and new directions. Nat. Rev. Drug Discov. 5 (2006) 577-584
18. Shay J.W., and Wright W.E. Hallmarks of telomeres in ageing research. J. Pathol. 211 (2007) 114-123
19. Harley C.B. Telomerase and cancer therapeutics. Nat. Rev. Cancer 8 (2008) 167-179
20. Liu J.P., Nicholls C., Chen S.M., Li H., and Tao Z.Z. Strategies of treating cancer by cytokine regulation of chromosome end remodelling. Clin. Exp. Pharmacol. Physiol. (2009)
21. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., and Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 266 (1994) 2011-2015
22. Lacerte A., Korah J., Roy M., Yang X.J., Lemay S., and Lebrun J.J. Transforming growth factor-beta inhibits telomerase through SMAD3 and E2F transcription factors. Cell. Signal. 20 (2008) 50-59
23. Harada K., Shintani Y., Sakamoto Y., Wakatsuki M., Shitsukawa K., and Saito S. Serum immunoreactive activin A levels in normal subjects and patients with various diseases. J. Clin. Endocrinol. Metab. 81 (1996) 2125-2130
24. Muttukrishna S., Fowler P.A., George L., Groome N.P., and Knight P.G. Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy. J. Clin. Endocrinol. Metab. 81 (1996) 3328-3334
25. Xu D., Dwyer J., Li H., Duan W., and Liu J.P. Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. J. Biol. Chem. 283 (2008) 23567-23580
26. Xu D., Popov N., Hou M., Wang Q., Bjorkholm M., Gruber A., Menkel A.R., and Henriksson M. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc. Natl. Acad. Sci. USA 98 (2001) 3826-3831